ClinicalTrials.gov term: Endometrial Neoplasms
Endometrial Cancer clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
59 trials changed in the last 30 days: 0 stopped, 30 with notable changes, 29 with minor changes only.
- Notable: RAINFOL-01 · Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Primary completion pushed from Jul 2027 to Dec 2028
- Notable: CAMPERR · CfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease Primary completion pushed from Mar 2026 to Dec 31, 2026
- Notable: CERBERO · Gut Microbiome · Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers Start date pushed from Oct 1, 2026 to Nov 11, 2026
- Minor: Zanidatamab · HER2-expressing Tumors Trial sites expanded: 28 → 42 locations
- Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations
- Minor: DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability Trial sites expanded: 23 → 30 locations
- Notable: KQB368 as Monotherapy · Advanced Solid Malignancies Recruitment opened
- Minor: Mocertatug Rezetecan Compared With Chemotherapy · Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) Trial sites expanded: 48 → 56 locations
- Minor: Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Trial sites expanded: 302 → 305 locations
- Notable: 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors Primary endpoint(s) modified
- Minor: RUBY-J · Dostarlimab in Combination With Carboplatin-paclitaxel · Primary Advanced or Recurrent Endometrial Cancer Primary completion pushed from Jul 15, 2026 to Dec 14, 2026
- Minor: DOVE · Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Enrollment closed, study ongoing
- Notable: ABILITY-1 · Beta-only IL-2 ImmunoTherapY Study Primary completion pushed from Nov 30, 2026 to Oct 20, 2028
- Notable: Symbiotic-GYN-18 · PF-08634404 in Combination With Chemotherapy · Advanced or Recurrent MMR-proficient Endometrial Cancer Recruitment opened
- Minor: EIK1005-002 · Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab · Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors Trial sites expanded: 35 → 45 locations
- Notable: LNCB74-01 · LNCB74 in Advanced Solid Tumors Primary and study completion pushed from Dec 2026 to Dec 2027
- Notable: PRO1107 · Advanced Solid Tumors Results posted: Oct 29, 2026
- Minor: Psilocybin-Assisted Psychotherapy in Cancer · Adjustment Disorder Primary completion pushed from Dec 30, 2026 to Mar 30, 2027
- Minor: OvAR-Y · Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women Trial completed
- Minor: XPORT-EC-042 · Selinexor in Maintenance Therapy After Systemic Therapy · p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Trial sites reduced: 191 → 185 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-04 | NCT07916610 Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for… | Barretos Cancer Hospital new | |
| 2026-11-02 | NCT07909031 CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. new | Phase 1/2 |
| 2026-10-29 | NCT07902999 HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line… | Shanghai Huaota Biopharmaceutical Co., Ltd. new | Phase 3 |
| 2026-10-28 | NCT07902375 Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for… | Universiteit Antwerpen new | |
| 2026-10-22 | NCT07890064 Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage… | Wang Yingmei new | Phase 2 |
| 2026-10-20 | NCT07882277 27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery | Metehan Uzundal new | |
| 2026-10-16 | NCT07877779 Protocol for Non-invasive Gynaecological Surveillance in Lynch Syndrome | University of Edinburgh new | |
| 2026-10-15 | NCT07874880 MTX-531-001 Phase 1 Study in Advanced Solid Tumors | MEKanistic Therapeutics, Inc. new | Phase 1 |
| 2026-10-13 | NCT07871838 Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for… | McGill University Health Centre/Research Institute of the McGill University Health Centre new | |
| 2026-10-08 | NCT07865650 PEG-rhG-CSF Primary Prophylaxis vs Therapeutic Short-Acting rhG-CSF for Neutropenia… | The Second Hospital of Anhui Medical University new |
Active trials by phase
| Early Phase 1 | 10 | |
| Phase 1 | 99 | |
| Phase 1/2 | 65 | |
| Phase 2 | 138 | |
| Phase 2/3 | 9 | |
| Phase 3 | 39 | |
| Phase 4 | 7 |
Not charted: 248 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (21) · Mayo Clinic (15) · Memorial Sloan Kettering Cancer Center (15) · AstraZeneca (13) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (13) · Peking University People's Hospital (13) · Dana-Farber Cancer Institute (11) · GlaxoSmithKline (10) · Eli Lilly and Company (7)
Get alerts when Endometrial Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.